Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 2,000
- 试验地点
- 1
- 主要终点
- To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+
研究概览
简要总结
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
详细描述
Retrospective, multi-institutional study focused on describing the clinical features, laboratory parameters, treatments, and outcomes among individuals presenting with HLH in the setting of a lymphoma
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with lymphoma that are fulfilling at least one of the following:
- •A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25>3,900 U/mL and ferritin>1,000 ng/mL)
排除标准
- •Patients developing HLH> 1 month after lymphoma diagnosis (for aggressive lymphomas)
- •Patients with incomplete treatment and response documentation
结局指标
主要结局
To determine the factors predicting 180 days overall survival of patients with cancer that are HLH-2004/OHI+
时间窗: The participant's survival would be assessed at 180 days from the malignancy diagnosis
The investigators will gather data on different treatments received, time to treatment, and other factors and determine which is associated with survival.
次要结局
未报告次要终点
研究者
Gaurav Goyal
Principal Investigator
University of Alabama at Birmingham